AKAN
Price
$3.45
Change
-$0.09 (-2.54%)
Updated
Sep 5 closing price
Capitalization
2.58M
SCYX
Price
$0.89
Change
+$0.02 (+2.30%)
Updated
Sep 5 closing price
Capitalization
37.31M
60 days until earnings call
Interact to see
Advertisement

AKAN vs SCYX

Header iconAKAN vs SCYX Comparison
Open Charts AKAN vs SCYXBanner chart's image
Akanda
Price$3.45
Change-$0.09 (-2.54%)
Volume$21.38K
Capitalization2.58M
SCYNEXIS
Price$0.89
Change+$0.02 (+2.30%)
Volume$191.49K
Capitalization37.31M
AKAN vs SCYX Comparison Chart in %
Loading...
AKAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKAN vs. SCYX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a Hold and SCYX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AKAN: $3.45 vs. SCYX: $0.89)
Brand notoriety: AKAN and SCYX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 18% vs. SCYX: 109%
Market capitalization -- AKAN: $2.58M vs. SCYX: $37.31M
AKAN [@Pharmaceuticals: Generic] is valued at $2.58M. SCYX’s [@Pharmaceuticals: Generic] market capitalization is $37.31M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 0 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • AKAN’s FA Score: 0 green, 5 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKAN and SCYX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 3 TA indicator(s) are bullish while SCYX’s TA Score has 6 bullish TA indicator(s).

  • AKAN’s TA Score: 3 bullish, 5 bearish.
  • SCYX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than AKAN.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а -5.74% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was +7.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

SCYX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCYX($37.3M) has a higher market cap than AKAN($2.58M). SCYX YTD gains are higher at: -26.446 vs. AKAN (-31.000). AKAN has higher annual earnings (EBITDA): -3.03M vs. SCYX (-19.29M). SCYX has more cash in the bank: 44.8M vs. AKAN (3.84M). AKAN has less debt than SCYX: AKAN (353K) vs SCYX (2.39M). SCYX has higher revenues than AKAN: SCYX (3.26M) vs AKAN (837K).
AKANSCYXAKAN / SCYX
Capitalization2.58M37.3M7%
EBITDA-3.03M-19.29M16%
Gain YTD-31.000-26.446117%
P/E RatioN/A0.91-
Revenue837K3.26M26%
Total Cash3.84M44.8M9%
Total Debt353K2.39M15%
FUNDAMENTALS RATINGS
SCYX: Fundamental Ratings
SCYX
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
20

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKANSCYX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend about 1 month ago
83%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
AKAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSTM14.590.64
+4.59%
Constellium SE
OMI5.620.22
+4.07%
Owens & Minor
LUNG1.74N/A
N/A
Pulmonx Corp
CR184.27-0.82
-0.44%
Crane Company
APDN2.39-0.49
-17.01%
Applied DNA Sciences Inc

AKAN and

Correlation & Price change

A.I.dvisor tells us that AKAN and SCYX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and SCYX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
-2.54%
SCYX - AKAN
31%
Poorly correlated
+2.43%
TLRY - AKAN
26%
Poorly correlated
+3.48%
CRON - AKAN
25%
Poorly correlated
N/A
SNOA - AKAN
25%
Poorly correlated
+4.42%
ANIK - AKAN
24%
Poorly correlated
-1.65%
More

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and AKAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and AKAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+2.43%
AKAN - SCYX
31%
Poorly correlated
-2.54%
ELAN - SCYX
30%
Poorly correlated
+5.50%
AQST - SCYX
30%
Poorly correlated
+7.11%
SIGA - SCYX
29%
Poorly correlated
-0.82%
ACET - SCYX
27%
Poorly correlated
+1.00%
More